Culture Medium Contains A Growth Factor Or Growth Regulator Patents (Class 435/384)
  • Patent number: 8815597
    Abstract: The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: August 26, 2014
    Assignee: Takara Bio Inc.
    Inventors: Hideto Chono, Junichi Mineno, Kazutoh Takesako, Takao Yoshida, Takashi Morimura, Kenji Sakai, Shin-ichi Yamada, Noritsugu Yabe, Yuko Taguchi
  • Patent number: 8802436
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 12, 2014
    Assignee: ACell, Inc.
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Patent number: 8802434
    Abstract: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: August 12, 2014
    Assignee: The University of Birmingham
    Inventor: Christopher Martin Bunce
  • Patent number: 8795530
    Abstract: The present invention relates to methods and systems for optimization of dilution of a viscous starting material to isolate and/or concentrate the product of interest from the starting source material such that the process minimizes the volume of diluent and the total volume of the waste stream generated during the process as well as maximizing the yield of desired product. The system employs cross-flow filtration modules with sub-channels that are equidistant to the inlet and outlet of said modules and such modules are characterized by optimal channel height, optimal transmembrane pressure, etc., which are selected in order to achieve the best combination of product quality and production yield.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: August 5, 2014
    Assignee: Smartflow Technologies, Inc.
    Inventors: Henry B. Kopf, James A. Kacmar
  • Patent number: 8785197
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 22, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 8785195
    Abstract: A microfiber showing improved mechanical strength, which comprises a micro gel fiber consisting of collagen gel or the like covered with high strength hydrogel such as alginate gel.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: July 22, 2014
    Assignee: The University of Tokyo
    Inventors: Shoji Takeuchi, Hiroaki Onoe, Yukiko Matsunaga, Daisuke Kiriya, Riho Gojo, Midori Negishi
  • Patent number: 8785194
    Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: July 22, 2014
    Assignee: Life Technologies Corporation
    Inventors: Stephen Gorfien, Richard Fike, Glenn Godwin, Joyce Dzimian, David A. Epstein, Dale Gruber, Don McClure, Paul Price
  • Patent number: 8785198
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 22, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 8772028
    Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: July 8, 2014
    Assignee: Sunnybrook Health Sciences Centre
    Inventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
  • Patent number: 8765470
    Abstract: Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 1, 2014
    Assignee: Cellular Dynamics International, Inc.
    Inventors: James Thomson, Deepika Rajesh, Sarah Jane Dickerson, Amanda Mack, Michael Miller
  • Publication number: 20140170693
    Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.
    Type: Application
    Filed: March 23, 2012
    Publication date: June 19, 2014
    Applicants: BRIGHAM AND WOMEN'S HOSPITAL, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventor: Tan A. Ince
  • Patent number: 8753885
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: June 17, 2014
    Assignee: CorMatrix Cardiovascular, Inc
    Inventor: Robert G Matheny
  • Patent number: 8753886
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 17, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 8748176
    Abstract: Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: June 10, 2014
    Assignee: The Regents of the University of California
    Inventors: Edwin S. Monuki, Momoko Watanabe
  • Patent number: 8741644
    Abstract: The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: June 3, 2014
    Assignee: Kyoto University
    Inventors: Tatsutoshi Nakahata, Kohichiro Tsuji, Feng Ma
  • Patent number: 8735155
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: May 27, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 8735149
    Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.
    Type: Grant
    Filed: April 5, 2009
    Date of Patent: May 27, 2014
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
  • Patent number: 8728815
    Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: May 20, 2014
    Assignee: University of Southern California
    Inventor: Valter Longo
  • Patent number: 8728814
    Abstract: Disclosed is an agent for improving at least one activity selected from the group consisting of the growth activity, adhesion activity and extension activity of mesenchymal stem cells, which comprises laminin-5 as an active ingredient. A method of culturing mesenchymal stem cells; a method of isolating mesenchymal stem cells; and a medium, vessel or sheet for use in culturing mesenchymal stem cells are also provided.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 20, 2014
    Assignee: Oriental Yeast Co., Ltd.
    Inventors: Kaoru Miyazaki, Junko Hashimoto, Yoshinobu Kariya
  • Patent number: 8728816
    Abstract: The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: May 20, 2014
    Assignee: Lek Pharmaceuticals D.D.
    Inventor: Tanja Ficko Trcek
  • Patent number: 8697139
    Abstract: Harvesting articular chondrocyte cells from a non-critical location of a patient and growing additional cells for transplantation into a damaged or diseased disc of the patient.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: April 15, 2014
    Inventor: Frank Martin Phillips
  • Patent number: 8685726
    Abstract: The present invention relates to compositions and methods for maintaining undifferentiated pluripotent stem cell cultures.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: April 1, 2014
    Assignee: Viacyte, Inc.
    Inventors: Thomas C Schulz, Allan J Robins
  • Publication number: 20140086882
    Abstract: The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. The invention has been developed primarily as a method for preparing and culturing BSC.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 27, 2014
    Applicant: Medela Holding AG
    Inventor: Foteini Hassiotou
  • Patent number: 8673318
    Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 18, 2014
    Assignee: Bavarian Nordic A/S
    Inventors: Ingmar Rathe, Eva Felder, Karl Heller
  • Patent number: 8652846
    Abstract: The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: February 18, 2014
    Assignee: Omnicyte Limited
    Inventors: Nagy A. Habib, Myrtle Gordon
  • Patent number: 8647872
    Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: February 11, 2014
    Assignee: H. Bion Co., Ltd.
    Inventors: Sung-Il Roh, Woo-Suk Hwang, Byeong-Chun Lee, Sung-Keun Kang, Young-June Ryu, Eu-Gene Lee, Soon-Woong Kim, Dae-Kee Kwon, Hee-Sun Kwon, Ja-Min Koo, Eul-Soon Park, Youn-Young Hwang, Hyun-Soo Yoon, Jong-Hyuk Park, Sun-Jong Kim
  • Patent number: 8642333
    Abstract: The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: February 4, 2014
    Assignees: Massachusetts Institute of Technology, Children's Hospital Boston
    Inventors: Lino da Silva Ferreira, Daniel Kohane, Robert Langer
  • Patent number: 8642335
    Abstract: Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: February 4, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roeland Nusse, Karl H. Willert
  • Patent number: 8642334
    Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: February 4, 2014
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Stuart Chambers, Lorenz Studer
  • Patent number: 8628963
    Abstract: The present invention relates to a medium composition comprising neuropeptide Y, effective for proliferation and maintenance of undifferentiated pluripotent stem cells, and a method for culturing undifferentiated pluripotent stem cells using the same. The present invention improves the culture conditions for undifferentiated pluripotent stem cells, and ultimately, the present invention can be effectively used for the development of large-scale culture systems, thereby acquiring clinically applicable pluripotent stem cells. Further, the present invention relates to a dedifferentiation medium composition comprising neuropeptide Y (NPY), and a method for inducing dedifferentiation (or reprogramming) using the same. The present invention improves the culture conditions for dedifferentiation and contributes to develop technology of producing clinically applicable induced pluripotent stem cells, thereby being used for the development of stem cell therapy.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: January 14, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yee Sook Cho, Mi-Young Son
  • Patent number: 8628962
    Abstract: Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: January 14, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: William J. Freed, Tandis Vazin
  • Publication number: 20140004556
    Abstract: Methods, compositions and kits are provided for generating inner ear cells in vitro. These methods find use a number of applications, such as in preparing inner ear cells for in vitro screening for agents that are toxic to inner ear cells, for in vitro screening for agents that prevent against, mitigate, or reverse the toxic effects of such agents, and for in vitro screening for agents that promote otoregeneration.
    Type: Application
    Filed: January 23, 2012
    Publication date: January 2, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stefan Heller, Mohammad Ronaghi, Kazuo Oshima
  • Patent number: 8617887
    Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.
    Type: Grant
    Filed: June 13, 2004
    Date of Patent: December 31, 2013
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michel Revel, Peter Lonai, Rozemari Stirbu Lonai
  • Publication number: 20130337562
    Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.
    Type: Application
    Filed: June 12, 2013
    Publication date: December 19, 2013
    Applicant: Regenerative Research Foundation
    Inventors: Jeffrey Stern, Sally Temple Stern
  • Patent number: 8609414
    Abstract: The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: December 17, 2013
    Inventors: Yupo Ma, Louis M. Fink, David C. Ward, Milton Waner
  • Patent number: 8597947
    Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: December 3, 2013
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventor: Benjamin Reubinoff
  • Publication number: 20130280801
    Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 24, 2013
    Applicant: LifeCell Corporation
    Inventor: Wenquan Sun
  • Patent number: 8563309
    Abstract: The present invention provides a method of producing a cell mass capable of serving as a primitive organ-like structure comprised of a plurality of somatic cell types of somatic origin, comprising: preparing cultures containing the plurality of types of somatic cells; mixing the plurality of types of somatic cell cultures followed by adding a Wnt signal activator to the mixed cell culture; subjecting the culture containing the Wnt signal activator to non-plate contact culturing over a predetermined time period; and replacing the medium of the culture cultured by the non-plate contact culturing with medium not containing Wnt signal activator and further culturing for a predetermined time period; wherein, at least one type of the plurality of somatic cells is maintained in an undifferentiated state.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: October 22, 2013
    Assignee: Shiseido Company, Ltd.
    Inventors: Shigeyoshi Fujiwara, Jiro Kishimoto, Tsutomu Soma
  • Patent number: 8563311
    Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: October 22, 2013
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 8541234
    Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: September 24, 2013
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Joseph Itskovitz-Eldor, Shahar Cohen
  • Publication number: 20130244262
    Abstract: The present invention provides a cardiomyocyte- and/or cardiac progenitor cell-proliferating agent comprising at least one compound selected from the group consisting of: a GSK3? inhibitor, ERK dephosphorylation inhibitor, Raf activator, CaMK2 inhibitor and p38 inhibitor; and a method for proliferating cardiomyocytes and/or cardiac progenitor cells using the agent.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 19, 2013
    Applicant: KYOTO UNIVERSITY
    Inventors: Jun Yamashita, Hideki Uosaki
  • Patent number: 8535944
    Abstract: The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: September 17, 2013
    Assignee: Minerva Biotechnologies Corporation
    Inventor: Cynthia C. Bamdad
  • Patent number: 8530235
    Abstract: The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway in the granulosa cell; and (iii) modulating activity of a BMP-6 dependent signalling pathway in a granulosa cell.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: September 10, 2013
    Assignee: Adelaide Research & Innovation Pty Ltd.
    Inventors: Robert B. Gilchrist, Jeremy Thompson, Tamer Hussein
  • Patent number: 8524494
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: September 3, 2013
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8524498
    Abstract: The methods and compositions described herein are based, in part, on the discovery of a stem cell state in human cells that resembles the morphology observed in murine-derived stem cells. Induction of such a state in human stem cells permits an increase in the efficiency of homologous recombination. Thus, the methods and compositions described herein relate to cells and methods for increasing the efficiency of homologous recombination in human stem cells.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: September 3, 2013
    Assignee: The General Hospital Corporation
    Inventors: Niels Geijsen, Christa Buecker
  • Patent number: 8518397
    Abstract: A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34+ hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: August 27, 2013
    Assignee: Case Western Reserve University
    Inventor: Rose C. Beck
  • Patent number: 8492149
    Abstract: The present invention relates to a method for inducing the differentiation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells with high efficiency, in which neural selection can be performed by the selected media and physical methods. The invention has advantages such as higher efficiency, the effect of lowering cost and time, and maintenance of neural progenitors for a longer period of time, as compared to the known methods for inducing the differentiation into neural progenitors, neurons, and dopaminergic neurons. Accordingly, the method can stably generate cells used for treating Parkinson's disease or other nervous system diseases.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 23, 2013
    Assignee: JE IL Pharmaceutical Co., Ltd.
    Inventors: Myung Soo Cho, Myung-Hwa Kim, Young-II Moon, Shin Yong Moon, Sun Kyung Oh, Hee Sun Kim, Dong-Wook Kim
  • Patent number: 8492080
    Abstract: The disclosure relates to the use of culture media containing thyroid hormones or analogs thereof, and includes methods and uses thereof for embryo culture, embryo production, embryo maturation, improved survival of embryos and improved viability of embryos post cryopreservation.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: July 23, 2013
    Assignee: University of Guelph
    Inventors: William Allan King, Fazl A. Ashkar
  • Patent number: 8489337
    Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: July 16, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Edward K. Y. Jung, Lowell L. Wood, Jr.
  • Publication number: 20130177537
    Abstract: Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 11, 2013
    Applicant: STEMEDICA CELL TECHNOLOGIES, INC.
    Inventor: Stemedica Cell Technologies, Inc.